Thursday, October 03, 2024 4:22:50 PM
This is too funny not to share!!!
This how hedge funds are looking at Rnaz right now!!!
https://www.facebook.com/share/r/dYJRbubWsj8GsNnN/?mibextid=11tuMg
This how hedge funds are looking at Rnaz right now!!!
https://www.facebook.com/share/r/dYJRbubWsj8GsNnN/?mibextid=11tuMg
Recent RNAZ News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/03/2026 09:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:39 PM
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Pa • PR Newswire (US) • 03/03/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:10:39 PM
- TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development • PR Newswire (US) • 02/23/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:10:42 PM
- TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 • PR Newswire (US) • 02/05/2026 01:04:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/07/2026 05:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:04:38 PM
- TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma • PR Newswire (US) • 01/06/2026 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/23/2025 09:17:28 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/23/2025 09:15:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2025 01:13:34 PM
- TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors • PR Newswire (US) • 12/22/2025 01:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/12/2025 09:17:03 PM
- TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial • PR Newswire (US) • 12/11/2025 01:05:00 PM
- TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer • PR Newswire (US) • 11/17/2025 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:03:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/27/2025 01:07:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2025 01:03:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/17/2025 09:10:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/17/2025 09:09:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 12:11:31 PM
